Table 3.
Treatment regimen variations in the intraperitoneal therapy, either in the neoadjuvant or adjuvant n (%)
| Treatment regimens | Total, n = 38 | Adjuvant group, n = 25 | Neoadjuvant group, n = 13 |
| Taxol 175 mg/m2, Carboplatin AUC 5 or 6 every 3 wk | 21 (55.3) | 14 (56) | 7 (54) |
| Carboplatin AUC 5 or 6, Taxol 80 mg/m2 day 1, 8, 15 every 3 wk (dose dense) | 3 (7.9) | 2 (8) | 1 (8)1 |
| Taxol 80 mg/m2 day 1, 8, Carboplatin AUC 2 day 1, 8 every 3 wk (weekly regimen) | 1 (2.6) | 0 (0) | 1 (8) |
| Carboplatin AUC 5 and Docetaxel 75 mg/m2 every 3 wk | 2 (5.2) | 1 (4) | 1 (8) |
| Carboplatin AUC 5 Gemcitabine 800 mg/m2 day 1, 8 every 3 wk (due to peripheral neuropathy) | 1 (2.6) | 1 (4) | 0 (0) |
| Carboplatin AUC 5 or 6, Abraxane D1, 8 every 3 wk (due to allergic reaction to Taxel) | 3 (7.9) | 1 (4) | 2 (15) |
| Carboplatin AUC with Taxol x1, with Docetaxel x1 and with Gemcitabine x1 (due to allergic reaction) | 1 (2.6) | 1 (4) | 0 (0) |
| No IV treatment, IP treatment only | 6 (15.8) | 5 (20) | 1 (8) |
| Completion of ≥ 6 cycles of IV + IP treatment | 34 (89.5) | 22 (88) | 12 (92) |
| Completion of 7-10 cycles of IV + IP | 5 (13.1) | 2 (8) | 3 (23) |
| Subsequent treatment with Bevacizumab at progression | 19 (50) | 13 (52) | 6 (46) |
1
This patient also received Bevacizumab with dose dense regimen in the neoadjuvant period. IP: Intraperitoneal; IV: Intravenous.